What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?
Would you use ALK inhibitors such as crizotinib based on recent phase II data?
Are there any research efforts to combine ALK inhibitors with current available therapies, such as brentuximab vedotin?
Community PollStarted
What chemotherapy backbone do you use with brentuximab/crizotinib for patients with relapsed/refractory ALCL?
8 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto
Answered on
I recently had an ALCL patient with small cell pathology which, as you know, is a poor prognostic pathology. I asked the same question, and the response from the COG expert, based on the unpublished data from ANHL12P1, was not to add targeted therapy up front but to base the decision on response. I also checked with the major NHL person from BFM and they too are not adding anything up front even for poor prognosis patients --at least yet.
So the suggestion right now is to add targeted therapy f...
Join for free or sign in to see the full answer